Eris Lifesciences is currently trading in the range of ₹1,371 to ₹1,474, with the latest reported price at ₹1,474.20 as of April 23, 2025. The stock has shown strong performance over the past year, delivering a return of approximately 57%. Over the last three months, the stock is up about 9%, though it has seen a slight dip of 0.57% in the past month.
**Valuation and Fundamentals**
Eris Lifesciences trades at a price-to-earnings (P/E) ratio of 57.13, which is high for the sector, and a price-to-book (P/B) ratio of 4.53. The company’s earnings per share (EPS) stands at 29.19, and its return on equity (ROE) is 12.63%, indicating moderate profitability. The market capitalization is approximately ₹18,831 crore[4]. The dividend yield is negligible, suggesting the company focuses more on growth than on returning cash to shareholders.
**Analyst Sentiment and Targets**
Analyst sentiment is strongly positive, with nearly 89% recommending a buy and the remainder suggesting hold; there are no sell recommendations. The average long-term price target from analysts is ₹1,512.56, indicating modest upside from current levels.
**Technical and Trading Overview**
The stock has recently traded near its upper circuit of ₹1,659.60, with a lower circuit at ₹1,106.40, reflecting a relatively wide trading band and potential for volatility. Recent trading volumes have been healthy, supporting the current price momentum.
**Summary**
Eris Lifesciences has delivered strong returns over the past year and is viewed positively by analysts. However, its high P/E ratio suggests the stock is priced for continued growth, and the lack of dividend yield may not appeal to income-focused investors. The technical outlook is stable, with the stock trading near its highs and supported by robust trading activity.
**Valuation and Fundamentals**
Eris Lifesciences trades at a price-to-earnings (P/E) ratio of 57.13, which is high for the sector, and a price-to-book (P/B) ratio of 4.53. The company’s earnings per share (EPS) stands at 29.19, and its return on equity (ROE) is 12.63%, indicating moderate profitability. The market capitalization is approximately ₹18,831 crore[4]. The dividend yield is negligible, suggesting the company focuses more on growth than on returning cash to shareholders.
**Analyst Sentiment and Targets**
Analyst sentiment is strongly positive, with nearly 89% recommending a buy and the remainder suggesting hold; there are no sell recommendations. The average long-term price target from analysts is ₹1,512.56, indicating modest upside from current levels.
**Technical and Trading Overview**
The stock has recently traded near its upper circuit of ₹1,659.60, with a lower circuit at ₹1,106.40, reflecting a relatively wide trading band and potential for volatility. Recent trading volumes have been healthy, supporting the current price momentum.
**Summary**
Eris Lifesciences has delivered strong returns over the past year and is viewed positively by analysts. However, its high P/E ratio suggests the stock is priced for continued growth, and the lack of dividend yield may not appeal to income-focused investors. The technical outlook is stable, with the stock trading near its highs and supported by robust trading activity.
Penafian
Maklumat dan penerbitan adalah tidak bertujuan, dan tidak membentuk, nasihat atau cadangan kewangan, pelaburan, dagangan atau jenis lain yang diberikan atau disahkan oleh TradingView. Baca lebih dalam Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak bertujuan, dan tidak membentuk, nasihat atau cadangan kewangan, pelaburan, dagangan atau jenis lain yang diberikan atau disahkan oleh TradingView. Baca lebih dalam Terma Penggunaan.